News Releases

News Releases

Synteract Presents Webinar on The Increasing Impact of Gene Therapy in Rare Oncology Clinical Trials

RESEARCH TRIANGLE PARK, NC – October 23, 2019Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, will host a webinar on “The Ever-Increasing Impact of Gene Therapy in Rare Oncology Trials” on Monday, November 18, 2019 at 8 a.m. PST/11 a.m. EST/4 p.m. BST/5 p.m. CEST. As gene therapy becomes more common in treating oncology diseases, it has the effect of turning almost every clinical trial into, essentially, a rare trial, because each person’s genetic code is unique. The complexity in these trials increases exponentially.

Synteract speakers include Christopher Heckman, vice president for Oncology Development, and Derek Ansel, director of Synteract’s Rare and Orphan Disease Center. They will address the unique questions and challenges engendered by this rapidly growing field, in which therapies may include alteration of genetic material within a person’s cells as a way of treating or preventing disease.  

As Heckman puts it, “Are we heading in the right direction? What are the ethical considerations? And how do we ensure access to these therapies? These are just a few of the questions that must be faced by today’s clinical researchers. Now we are not only working with oncogenic drivers, but also the very genetic code that makes each of us the same, yet unique.”

The webinar will provide an overview of the impact of gene therapy innovation on rare oncology clinical development and presenters will discuss challenges, strategies and real-life solutions to support patients, investigative sites, and drug developers. Those interested in learning more can register here.

About Synteract
“Bringing Clinical Trials to Life” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. Synteract supports biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries. It has contributed to more than 240 product approvals. Synteract offers a notable depth of expertise in oncology, general medicine, dermatology, neuroscience, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter.

# # #
CONTACT:
Beth Walsh
beth@clearpointagency.com
760-230-2424

x

Submit RFI / RFP

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Contact Synteract

Tell us how to stay in touch with you:

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

 

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required

x

To complete your download, please choose an option in the Internet Explorer pop-up window at the bottom of this browser.

x

Opt In

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required